Healthcare
Alpha Cognition Secures $44 Million Licensing Deal with CMS for ZUNVEYL in Asia-Pacific
Agreement Paves the Way for Advanced Alzheimer’s Treatment in China and Beyond Alpha Cognition (ACOG), a biopharmaceutical company at the...
Telomir Pharmaceuticals Unveils Groundbreaking Progeria Treatment in Preclinical Study
Novel Therapy Shows Promise in Restoring Lifespan and Addressing Accelerated Aging Telomir Pharmaceuticals (TELO), a leader in age-reversal science, has...
Traws Pharma Advances Bird Flu Treatment with Promising Phase 1 Results
Tivoxavir Marboxil Shows Potent Protection Against H5N1 in Preclinical and Early Clinical Studies Traws Pharma (TRAW), a clinical-stage biopharmaceutical company,...
Telomir Pharmaceuticals Advances Groundbreaking Research in Copper-Binding Therapies for Wilson’s Disease
Emerging Findings Position Telomir-1 as a Promising Solution for Copper Metabolism Disorders and Expand Its Potential Applications Telomir Pharmaceuticals (TELO),...
Novo Nordisk’s CagriSema Trial Results Shake Market Confidence
Disappointing Data Spurs $125 Billion Market Value Drop Novo Nordisk’s (NVO) ambitions in the competitive obesity drug market took a...
MIRA Pharmaceuticals Advances Ketamir-2: A Safe Step Forward in Neuropathic Pain Treatment
Favorable safety results pave the way for Phase 1 human trials in early 2025, offering hope for millions seeking non-addictive...
Telomir Pharmaceuticals Unveils Groundbreaking Results in Age-Reversal Science with Telomir-1
Preclinical Study Highlights Significant Longevity Benefits, Sets Stage for Human Trials Telomir Pharmaceuticals (Nasdaq: TELO) has announced groundbreaking preclinical results...
Cigna Ends Speculation Over Humana Merger, Citing M&A Strategy and Financial Criteria
Health insurer clarifies position amid investor interest following Trump’s re-election and merger hopes Cigna Group (CI) has officially stated it...
BioMarin Pharmaceuticals’ New Strategy Promises Strong Upside, Led by Voxzogo and Roctavian
Wedbush Sees Favorable Risk/Reward as BioMarin Targets Growth in Rare Disease Market BioMarin Pharmaceuticals (BMRN), a leader in rare disease...
Viking Therapeutics’ VK2735 Demonstrates Promising Weight Loss Results in Phase 1 and Phase 2 Trials
Clinical Data from Oral and Subcutaneous Doses Show Effective Weight Loss and Support Potential for Long-Term Dosing Strategies Viking Therapeutics...
